CPC C07K 16/2818 (2013.01) [A61K 9/0053 (2013.01); A61K 31/444 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01)] | 17 Claims |
1. A method for treating cancer in a subject in need thereof, the method comprising administering to the subject, an anti-PD-1 antibody and apatinib or a pharmaceutically acceptable salt thereof, wherein the anti-PD-1 antibody comprises:
an antibody light chain variable region comprising LCDR1, LCDR2 and LCDR3 having the amino acid sequences of SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, respectively; and
an antibody heavy chain variable region comprising HCDR1, HCDR2 and HCDR3 having the amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, respectively,
wherein the apatinib or the pharmaceutically acceptable salt thereof is administered orally at a dose from 125 mg to 375 mg.
|